FOSCARNET SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Foscarnet Sodium patents expire, and what generic alternatives are available?
Foscarnet Sodium is a drug marketed by Amneal, Avet Lifesciences, Beijing, Fresenius Kabi Usa, Gland Pharma Ltd, and Hospira. and is included in six NDAs.
The generic ingredient in FOSCARNET SODIUM is foscarnet sodium. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the foscarnet sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Foscarnet Sodium
A generic version of FOSCARNET SODIUM was approved as foscarnet sodium by FRESENIUS KABI USA on January 29th, 2021.
Summary for FOSCARNET SODIUM
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Clinical Trials: | 24 |
Patent Applications: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FOSCARNET SODIUM at DailyMed |
Recent Clinical Trials for FOSCARNET SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cttq | Phase 4 |
Peking University People's Hospital | Phase 4 |
City of Hope Medical Center |
Pharmacology for FOSCARNET SODIUM
Drug Class | Pyrophosphate Analog DNA Polymerase Inhibitor |
Mechanism of Action | Chelating Activity DNA Polymerase Inhibitors |